Litcius/Paper detail

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

Roger Li, Nancy Villa, Xiaoqing Yu, Joseph Johnson, Gustavo Borjas, Jasreman Dhillon, Carlos Moran Segura, Young‐Chul Kim, Natasha Francis, Denise Dorman, John J. Powers, Wade J. Sexton, Philippe E. Spiess, Michael Poch, Logan Zemp, Scott M. Gilbert, Jingsong Zhang, Julio M. Pow‐Sang, Alexander R.A. Anderson, Tingyi Li, Xuefeng Wang, G. Daniel Grass, James M. Burke, Colin P. Dinney, Paulo C. Rodrı́guez, Rohit Jain, James J. Mulé, José R. Conejo-García

2024Nature Medicine29 citationsDOIOpen Access PDF

Topics & Concepts

NivolumabOncolytic virusImmunotherapyBladder cancerMedicineCancer immunotherapyOncologyInternal medicineCancer researchCancerBladder and Urothelial Cancer TreatmentsCancer Research and TreatmentsImmunotherapy and Immune Responses
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial | Litcius